If you live in Nevada and are researching compounded GLP-1 medications, this page is meant to save you some digging. It explains how access works in the state, what Nevada’s telehealth prescribing rules actually require, what the Nevada State Board of Pharmacy has said about compounded semaglutide and tirzepatide (it has been unusually direct), what these medications cost, and how several providers serving Nevada compare on published cash prices. Everything here is drawn from public sources, with links, so you can check our work.
One disclosure up front: this site is operated by Gentle Health, a telehealth provider offering compounded GLP-1 treatment for weight management. Gentle Health appears in the comparison table below on the same terms as every other provider listed, and nothing on this page ranks one provider over another.
How compounded GLP-1 access works in Nevada
Nevada does not require an in-person clinic visit to be evaluated for a GLP-1 prescription. Under NRS 629.515, a provider at a distant site may direct or manage care, render a diagnosis, or write a prescription for a patient located in Nevada through telehealth, so long as the provider holds a valid Nevada license and meets the same standard of care that would apply in an exam room. The statute also makes clear that the encounter is governed by Nevada law, wherever the provider happens to sit.
Here is what that looks like in practice for a Gentle Health patient in Nevada:
- Complete a medical intake. You answer questions about your health history, current medications, and goals. This is the information a physician needs to decide whether a GLP-1 is appropriate for you.
- Physician review. Your intake is reviewed by James Simmons, MD, who is licensed to practice in Nevada through the Interstate Medical Licensure Compact (license 30009, state board record), of which Nevada is a member state. Dr. Simmons evaluates every Nevada patient individually; not everyone who applies is approved.
- Prescription and fulfillment. If Dr. Simmons determines treatment is appropriate, the prescription is sent to a licensed compounding pharmacy, and the medication ships to your home anywhere in Nevada, from Laughlin to Jackpot.
- Ongoing care. Dosing is adjusted over time based on how you respond, and you can reach Dr. Simmons with questions between check-ins.
The practical upshot: a patient in Elko or Tonopah has the same access as a patient in Las Vegas. That matters in a state where two metro areas hold nearly all the specialists and everything between them is some of the emptiest highway in the country. Nevada is the seventh-largest state by land area, and most of its counties have no obesity-medicine specialist at all.
A note on the Compact, since it comes up: Nevada adopted the IMLC by statute, in NRS Chapter 629A, and a license issued through it is not a lighter version of a Nevada license. It is a full, unrestricted license issued by the Nevada State Board of Medical Examiners, and a physician who holds one answers to that board like any other Nevada licensee. What the Compact changes is the paperwork timeline for qualified physicians already licensed in other member states.
The Nevada-specific licensing record, with its board-verification link, is on our Nevada page. Every state we serve, each with its license number and board-verification link, is listed on our states page.
Nevada rules worth knowing
Two threads matter here: how Nevada regulates telehealth prescribing, and what the state’s Board of Pharmacy has said about compounded GLP-1s specifically. On the second thread, Nevada has been one of the most explicit states in the country, and anyone considering compounded treatment here should read this section before reading any price.
Telehealth prescribing. Nevada’s core telehealth statute is NRS 629.515, and the Center for Connected Health Policy maintains a current summary of Nevada’s telehealth rules. A few points worth knowing:
- Before a provider at a distant site can direct care, diagnose, or prescribe for a patient located in Nevada, the provider must hold a valid Nevada license or certificate, including, in some cases, a special purpose license issued under NRS 630.261.
- A provider-patient relationship can be established through telehealth, subject to the conditions in the statute. It must actually be established: a real evaluation of your history and current condition, not a checkout page.
- Care delivered through telehealth is held to the same standard as in-person care, and Nevada law governs the encounter. There is no separate, looser standard for online visits.
- GLP-1 medications are not controlled substances, so the stricter state and federal rules that govern telehealth prescribing of controlled substances do not apply here.
The Board of Pharmacy’s 2025 notice. This is the part of the Nevada picture that most marketing pages skip, and it is the part you should read most carefully. On June 2, 2025, the Nevada State Board of Pharmacy sent a formal notice to its licensees and registrants relaying the FDA’s declaratory orders that resolved the national shortages of tirzepatide (December 19, 2024) and semaglutide (February 21, 2025) injection products. The notice tells pharmacies, in plain terms, that they “must comply with both Declaratory Orders and cease the compounding, distributing, and dispensing of compounded tirzepatide injection and semaglutide injection products” as of the effective dates, which have all now passed. It applies to both traditional 503A compounding pharmacies and 503B outsourcing facilities.
The notice does three more things worth knowing about. It points pharmacies to the FDA’s January 2018 guidance on compounded drugs that are “essentially copies” of commercially available products, which is where the narrow, patient-specific exceptions to the general rule live. It reminds 503A pharmacies that they may not sell compounded medications to practitioners for office use. And it warns that continued compounding, distribution, or dispensing of these injection products after the effective dates violates Nevada law, citing NRS 639.100, NRS 639.233, NRS 639.288, NRS 639.310, and NAC 639.593, with fines available under NRS 639.2895. Pharmacies are also directed to the state’s compounding regulation, NAC 639.757, as amended effective November 15, 2024.
What this means for a patient. The Board’s notice is aimed at pharmacies, not patients, and it tracks federal law rather than inventing a separate Nevada ban. But the practical effect is real: with the shortages resolved, large-scale compounding of these injection products is over, and what room remains under Section 503A of the Food, Drug and Cosmetic Act is the narrow, individualized lane: a prescription written for a specific patient where the prescriber has determined that a compounded formulation serves that patient’s clinical needs, evaluated against the FDA’s essential-copies framework. The FDA’s own statements describe the same shift, and federal scrutiny of this space has continued through 2026.
None of this is a reason to stop asking questions. It is a reason to ask more of them, and to be suspicious of any provider who will not answer these three: who is prescribing, which pharmacy is compounding, and whether that pharmacy is licensed for Nevada and operating within the current federal framework. A provider who treats the Board’s notice as a secret is telling you something.
Compounded semaglutide in Nevada
Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your body already makes, one that signals fullness, slows how quickly your stomach empties, and helps regulate blood sugar. The practical effect most patients describe is that food quiets down: smaller portions satisfy, and the constant background negotiation with appetite eases.
Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient, based on a prescription. It is not FDA-approved, and that is a factual difference worth understanding rather than a footnote: compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality before dispensing. Oversight comes instead from state boards of pharmacy and from the prescribing physician’s judgment about the individual patient. In Nevada, as the section above explains, the Board of Pharmacy has directed pharmacies to stop compounding and dispensing semaglutide injection products in line with federal law, so any compounded option offered here has to fit within the narrow patient-specific exceptions of that framework, and you should ask any provider, this one included, how theirs does.
Gentle Health offers compounded semaglutide in two forms, at dose-tiered cash prices:
- Oral semaglutide: starting at $112 per month. Taken daily, no needles involved.
- Injectable semaglutide: starting at $135 per month. A once-weekly subcutaneous injection with a small needle.
Both prices are cash-pay and dose-tiered; the monthly price changes if the prescribed dose moves into a different tier. Treatment is subject to medical evaluation by Dr. Simmons, and continuing care is included rather than billed separately.
Compounded tirzepatide in Nevada
Tirzepatide works on two hormone receptors rather than one: GLP-1 and GIP. Like semaglutide, it is prescribed for weight management alongside changes to eating and activity; the dual mechanism is the main pharmacological distinction between the two medications. Which one is appropriate for a given patient, if either, is a clinical decision rather than a menu choice, and it depends on health history, other medications, and how a patient responds over time.
Compounded tirzepatide, like compounded semaglutide, is prepared for an individual patient by a licensed compounding pharmacy and is not FDA-approved. The Nevada Board of Pharmacy’s 2025 notice covered tirzepatide injection products on the same terms as semaglutide, so the same questions about the patient-specific compounding lane apply here.
Gentle Health offers compounded injectable tirzepatide starting at $169 per month, cash-pay, priced according to the prescribed dose tier, once weekly. As with semaglutide, the evaluation, the prescription decision, and ongoing dose adjustments are handled by James Simmons, MD.
Provider options in Nevada: comparison table
Methodology: rows are ordered alphabetically; prices were taken only from each provider’s public web pages (each row shows its verification date), and where a provider does not publish a price we say “See site” rather than guessing. Gentle Health operates this site and is listed on the same terms as everyone else. We do not rank providers.
| Provider | Care model | Compounded semaglutide (cash/mo) | Compounded tirzepatide (cash/mo) | Serves Nevada | Insurance | Source |
|---|---|---|---|---|---|---|
| Body Balance Medical | In-person clinic (Las Vegas); all-inclusive monthly program | $299 | See site | Yes (Las Vegas, Henderson, Summerlin) | Cash-pay; HSA/FSA accepted | bodybalancemedical.com (verified 2026-07-30) |
| Eden | Telehealth; medication price plus separate membership ($39 first month, then $99/mo) | $99 + membership | $199 + membership | See site (state availability not listed) | Not required; HSA/FSA eligible | eden.health (verified 2026-07-30) |
| Gentle Health (operates this site) | Telehealth; care by James Simmons, MD; dose-tiered pricing, no separate membership fee | From $112 oral / from $135 injectable | From $169 | Yes | No insurance; cash-pay only | gentle.health (verified 2026-07-27) |
| Mochi Health | Telehealth; medication price plus $79/mo membership | $99 + membership | $199 + membership | Yes (serves all US states per its FAQ) | See site | joinmochi.com (verified 2026-07-30) |
| Noom Med | Telehealth; low-dose program bundling care and medication, billed $537 per 12 weeks after intro | From $179 (low-dose program) | See site | See site (Noom states it is not available in all 50 states) | Not required; FSA/HSA eligible | noom.com (verified 2026-07-30) |
| Weight Method | Telehealth; program price includes evaluation, medication, ongoing care, delivery | From $199 | From $329 | Yes (Nevada-licensed providers per its Las Vegas pages) | No insurance; direct-pay | weightmethod.com (verified 2026-07-27) |
A few reading notes. Headline medication prices and total monthly cost are not the same thing: where a provider charges a separate membership fee, your real monthly outlay is the sum of the two lines. Intro prices are common in this market, so it is worth checking what month four costs, not just month one. In-person programs often price by dose tier or by what is bundled, so ask what happens to the bill as your dose changes. And every provider on this list requires a medical evaluation; a price is only relevant if a licensed prescriber determines treatment is appropriate for you, and, in Nevada, only if the dispensing pharmacy is operating within the rules described above.
For a year-long, all-fees-included view of how the major programs price out, see our full comparison of what GLP-1 programs actually cost.
Frequently asked questions: compounded GLP-1 in Nevada
Is compounded semaglutide legal in Nevada? The honest answer is: within narrow limits, and Nevada has been blunter about those limits than most states. Compounding for an individual patient under a valid prescription is permitted under federal law (Section 503A) when the pharmacy is properly licensed and the product is not an essential copy of a commercially available drug. But the Nevada Board of Pharmacy’s June 2025 notice directed pharmacies to cease compounding and dispensing semaglutide and tirzepatide injection products now that the federal shortages are resolved, pointing to the FDA’s essential-copies guidance for its “very limited exceptions.” Any provider offering compounded treatment in Nevada should be able to explain how its pharmacy operates within that framework. Ask.
Do I need an in-person doctor visit to get a GLP-1 prescription in Nevada? No. Under NRS 629.515, a provider-patient relationship can be established through telehealth, and a properly licensed provider can evaluate, diagnose, and prescribe remotely for a patient located in Nevada. The provider must hold a Nevada license, and the care is held to the same standard as an in-person visit. See the Center for Connected Health Policy’s Nevada summary for the current rules.
Who prescribes for Gentle Health patients in Nevada? James Simmons, MD, who is licensed to practice medicine in Nevada through the Interstate Medical Licensure Compact, which Nevada adopted in NRS Chapter 629A. A Compact license is a full Nevada license issued by the Nevada State Board of Medical Examiners. Every prescription decision at Gentle Health is made by Dr. Simmons based on an individual medical evaluation.
What did the Nevada Board of Pharmacy’s 2025 notice actually say? It relayed the FDA’s declaratory orders resolving the tirzepatide and semaglutide injection shortages and told Nevada-licensed pharmacies, both 503A and 503B, to stop compounding, distributing, and dispensing those injection products as of the stated effective dates, all of which have passed. It directed pharmacies to the FDA’s 2018 essential-copies guidance for the remaining narrow exceptions, reminded 503A pharmacies they cannot sell compounded drugs to practitioners for office use, and listed the Nevada statutes a violation would implicate. You can read the notice itself; it is two pages and unusually clear.
Does insurance cover compounded GLP-1s in Nevada? Generally, no. Insurance plans typically do not cover compounded medications. Most providers in this market, Gentle Health included, are cash-pay. Some accept HSA or FSA funds; check the individual provider’s site.
How does the medication get to me? After a prescription is issued, a licensed compounding pharmacy prepares your medication and ships it to your address in Nevada. Pharmacies dispensing into Nevada must be licensed with the State Board of Pharmacy, which is how the Board’s rules, including the 2025 notice above, reach mail-order pharmacies located out of state. Shipments are packaged for temperature control where the formulation requires it.
Can I get compounded GLP-1 treatment outside Las Vegas and Reno? Yes, anywhere in the state. Because the model is telehealth plus home delivery, a patient in Winnemucca, Ely, or Pahrump has the same access as a patient in Henderson or Sparks. That is arguably where telehealth matters most in Nevada: outside the two metro areas, specialist care is scarce and the drives are measured in hours, not minutes.
Current Gentle Health dose tiers and pricing
Gentle Health pricing depends on the dose tier prescribed by your clinician. Current monthly prices are:
Oral compounded semaglutide
| Tier | Daily dose | Monthly price |
|---|---|---|
| Starting | 2-4 mg/day | $112/mo |
| Medium | >4-8 mg/day | $189/mo |
| High dose | >8-12 mg/day | $258/mo |
Injectable compounded semaglutide
| Tier | Weekly dose | Monthly price |
|---|---|---|
| Starting | 0.24-0.48 mg/wk | $135/mo |
| Medium | >0.48-1.2 mg/wk | $159/mo |
| High dose | >1.2-2.4 mg/wk | $199/mo |
Injectable compounded tirzepatide
| Tier | Weekly dose | Monthly price |
|---|---|---|
| Starting | 2.5-5 mg/wk | $169/mo |
| Medium | >5-10 mg/wk | $219/mo |
| High dose | >10-15 mg/wk | $269/mo |
Medication, the initial review by a licensed clinician, video visits and messaging, and overnight refrigerated shipping are included. There is no separate membership fee, and HSA and FSA cards are accepted. Your clinician determines the appropriate medication and dose; the monthly price changes if the prescribed dose moves into a different tier.
Gentle Health serves patients across a growing multistate footprint through clinicians licensed in each patient’s jurisdiction, including Nevada.
Reviewed by James Simmons, MD
Compounded medications are not FDA-approved. Treatment subject to medical evaluation.